Long-Term Follow-Up of Sorafenib or Placebo in Patients With Newly Diagnosed AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sorafenib or Placebo in Patients With Newly Diagnosed Acute Myeloid Leukaemia: Long-Term Follow-Up of the Randomized Controlled SORAML Trial
Leukemia 2021 Feb 18;[EPub Ahead of Print], C Röllig, H Serve, R Noppeney, M Hanoun, U Krug, CD Baldus, CH Brandts, V Kunzmann, H Einsele, A Krämer, C Müller-Tidow, K Schäfer-Eckart, A Neubauer, A Burchert, A Giagounidis, SW Krause, A Mackensen, W Aulitzky, R Herbst, M Hänel, N Frickhofen, J Kullmer, U Kaiser, A Kiani, H Link, T Geer, A Reichle, C Junghanß, R Repp, A Meinhardt, H Dürk, IM Klut, M Bornhäuser, M Schaich, S Parmentier, M Görner, C Thiede, M von Bonin, U Platzbecker, J Schetelig, M Kramer, WE Berdel, G EhningerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.